Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

University of Oxford Skyline

The highly competitive Cancer Research UK Centre awards recognise the UK’s most innovative, high-impact cancer research and NHS-University collaborations. This coveted funding, announced today, will see £11 million invested in Oxford and the Thames Valley’s cancer research and translational infrastructure, and a further £3 million into training over the next 5 years.

Cancer remains the second largest cause of global mortality, impacting the lives of millions worldwide. Half of us will be diagnosed with cancer, and there is a strong demand for investment in academic excellence, and to support partnerships with industry and public health organisations.

Within Oxford, the funding will draw together academics and experts from across its fundamental, translational and clinical research communities including from cancer doctors, mathematicians, computer & data scientists, vaccinologists, immunologists, cellular biologists, drug discovery experts, clinical trialists, imaging experts and public health specialists. Nationally and internationally, the new investment will foster a multisectoral approach and invest partnerships that will deliver short and long term patient benefit.

Read the full story on the Oxford Cancer website.